Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jul 14:13:913749.
doi: 10.3389/fendo.2022.913749. eCollection 2022.

Effect of Levothyroxine on Older Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis

Chunyan Zhao  1 , Yueqi Wang  1 , Liu Xiao  1 , Lin Li  1
Affiliations
Meta-Analysis

Effect of Levothyroxine on Older Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis

Chunyan Zhao et al. Front Endocrinol (Lausanne). .

Abstract

Background: Subclinical hypothyroidism (SCH) is usually treated with levothyroxine, but there is controversy as to whether SCH should be treated, especially for older patients. The aim of the systematic review and meta-analysis was to evaluate whether levothyroxine has a beneficial or harmful effect on older patients with SCH.

Methods: Databases including PubMed, Embase, Cochrane Library, Web of Science, Wanfang, Weipu and China National Knowledge Infrastructure were searched from inception until December 21, 2021. Subjects must be diagnosed with SCH, and older than or equal to 60 years of age. Interventions should be thyroid hormone therapy (e.g. levothyroxine). The literature was independently screened by 2 researchers. Statistical analysis was performed using RevMan5.3 software.

Results: A total of 13 articles were included. Meta-analysis results showed that in older SCH patients, levothyroxine can significantly reduce cholesterol (TC) (p < 0.00001), triglyceride (TG) (p < 0.00001), low-density lipoprotein cholesterol (LDL-C) (p = 0.03) and apolipoprotein B (ApoB) (p < 0.00001). In addition, levothyroxine had no significant effect on bone mineral density, fatigue, hypothyroidism symptoms, quality of life, BMI, cognitive function, depression, blood pressure, etc. in older SCH patients, and also did not significantly increase the incidence of adverse events.

Conclusions: Among older SCH patients, levothyroxine treatment may reduce TC, TG, LDL-C, and ApoB.

Keywords: apolipoprotein B; cholesterol; levothyroxine; low-density lipoprotein cholesterol; older; subclinical hypothyroidism; triglyceride.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Meta-analysis flowchart. This meta-analysis included a total of four steps: Identification, Screening, Eligibility and Included. CNKI, China National Knowledge Infrastructure.
Figure 2
Figure 2
Forest plots depicting the effect of levothyroxine on the bone mineral density, fatigue, hypothyroidism symptoms and quality of life in older patients. (A) Association between levothyroxine and bone mineral density. (B) Association between levothyroxine and fatigue. (C) Association between levothyroxine and hypothyroidism symptoms. (D) Association between levothyroxine and quality of life.
Figure 3
Figure 3
Forest plots depicting the effect of levothyroxine on the BMI, cognitive function, depression and serum creatinine in older patients. (A) Association between levothyroxine and BMI. (B) Association between levothyroxine and cognitive function. (C) Association between levothyroxine and depression. (D) Association between levothyroxine and serum creatinine. BMI, Body Mass Index.
Figure 4
Figure 4
Forest plots depicting the effect of levothyroxine on the systolic blood pressure, diastolic blood pressure, fasting blood glucose, HDL-C and apolipoprotein A in older patients. (A) Association between levothyroxine and systolic blood pressure. (B) Association between levothyroxine and diastolic blood pressure. (C) Association between levothyroxine and fasting blood glucose. (D) Association between levothyroxine and HDL-C. (E) Association between levothyroxine and apolipoprotein A. HDL-C, High-Density Lipoprotein Cholesterol.
Figure 5
Figure 5
Forest plots depicting the effect of levothyroxine on the cholesterol, triglyceride, LDL-C and apolipoprotein B in older patients. (A) Association between levothyroxine and cholesterol. (B) Association between levothyroxine and triglyceride. (C) Association between levothyroxine and LDL-C. (D) Association between levothyroxine and apolipoprotein B. LDL-C, Low-Density Lipoprotein Cholesterol.
Figure 6
Figure 6
Forest plots depicting the effect of levothyroxine on the fatal or nonfatal cardiovascular event, cardiovascular death, all-cause death, atrial fibrillation, heart failure and number of patients with ≥1 serious adverse event in older patients. (A) Association between levothyroxine and fatal or nonfatal cardiovascular event. (B) Association between levothyroxine and cardiovascular death. (C) Association between levothyroxine and all-cause death. (D) Association between levothyroxine and atrial fibrillation. (E) Association between levothyroxine and heart failure. (F) Association between levothyroxine and number of patients with ≥1 serious adverse event.
See this image and copyright information in PMC

References

    1. Peeters RP. Subclinical Hypothyroidism. New Engl J Med (2017) 377(14):1404. doi: 10.1056/NEJMcp1611144 - DOI - PubMed
    1. Calissendorff J, Falhammar H. To Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence? Medicina (Kaunas) (2020) 56(1):40. doi: 10.3390/medicina56010040 - DOI - PMC - PubMed
    1. Biondi B, Cooper DS. The Clinical Significance of Subclinical Thyroid Dysfunction. Endocr Rev (2008) 29(1):76–131. doi: 10.1210/er.2006-0043 - DOI - PubMed
    1. Cooper DS, Biondi B. Subclinical Thyroid Disease. Lancet (2012) 379(9821):1142–54. doi: 10.1016/S0140-6736(11)60276-6 - DOI - PubMed
    1. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. . Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid (2014) 24(12):1670–751. doi: 10.1089/thy.2014.0028 - DOI - PMC - PubMed